Abstract
Purpose of Review
We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension.
Recent Findings
Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C. Treatment with any of the three currently FDA-approved SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) results in sustained systolic and diastolic blood pressure reduction, in part via minimal natriuresis and possible reductions in sympathetic tone. Recent randomized clinical trials in high cardiovascular risk patients with type 2 diabetes suggest that the unique effects of SGLT2 inhibitors on blood pressure and body weight may translate into reduced cardiovascular events and slowed kidney disease progression. However, concerns about volume depletion and acute kidney injury have been raised.
Summary
SGLT2 inhibitors are viable second-line glucose-lowering agents for people with type 2 diabetes with high cardiovascular risk.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Fuller JH. Epidemiology of hypertension associated with diabetes mellitus. Hypertension. 1985;7(6 Pt 2):II3–7.
Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19(5):403–18. https://doi.org/10.1161/01.HYP.19.5.403.
Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002;106(16):2085–90. https://doi.org/10.1161/01.CIR.0000033824.02722.F7.
Cherney DZ, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13(1):28. https://doi.org/10.1186/1475-2840-13-28.
Nosadini R, Sambataro M, Thomaseth K, Pacini G, Cipollina MR, Brocco E, et al. Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney Int. 1993;44(1):139–46. https://doi.org/10.1038/ki.1993.224.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998. 352(9131): p. 854–65.
•• DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26. Comprehensive review paper discussing all the relevant literature regarding metabolic and hemodynamic effects of the SGLT 2 class.
Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63–71. https://doi.org/10.1016/j.tips.2010.11.011.
Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75–83. https://doi.org/10.1152/ajpregu.00357.2011.
Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68(6):1355–64. https://doi.org/10.1161/HYPERTENSIONAHA.116.07703.
Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–312. https://doi.org/10.2165/11209910-000000000-00000.
Lamos EM, Younk LM, Davis SN. Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013;9(6):763–75. https://doi.org/10.1517/17425255.2013.791282.
Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–25. https://doi.org/10.1007/s40262-013-0126-x.
Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–80. https://doi.org/10.2147/DDDT.S50773.
•• Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. Major CV outcome trial with empagliflozin demonstrating reduced CV risk and some renoprotection.
•• Neal, B., et al., Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017.-online. Second major CV outcome trial with canagliflozin that is consistent with empagliflozin data and demonstrates major reduction in CV risk in type 2 diabetes patients.
Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–94. https://doi.org/10.1152/physrev.00055.2009.
Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev. 1994;74(4):993–1026. https://doi.org/10.1152/physrev.1994.74.4.993.
DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36(10):3169–76. https://doi.org/10.2337/dc13-0387.
Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–42. https://doi.org/10.1111/j.1464-5491.2009.02894.x.
Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5):e001007. https://doi.org/10.1136/bmjopen-2012-001007.
Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375–93. https://doi.org/10.3109/07853890.2011.560181.
Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74. https://doi.org/10.7326/0003-4819-159-4-201308200-00007.
Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complicat. 2015;29(8):1295–303. https://doi.org/10.1016/j.jdiacomp.2015.07.011.
Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951–9. https://doi.org/10.1111/j.1463-1326.2012.01659.x.
• Mazidi, M., et al., Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc, 2017. 6(6). Doi: https://doi.org/10.1161/JAHA.116.004007. Important meta-analysis that evaluates studies of glycemic control and outcomes with the class.
• Baker, W.L., et al., Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc, 2017. 6(5). Important summary of ABPM data and SGLT2 inhibitors-provides a balanced summary out BP outcomes.
Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–8. https://doi.org/10.2337/dc11-1926.
Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592–8. https://doi.org/10.1177/0091270008316885.
Gill A, Hoogwerf BJ, Burger J, Bruce S, MacConell L, Yan P, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9(1):6. https://doi.org/10.1186/1475-2840-9-6.
Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38(1):132–9. https://doi.org/10.2337/dc14-1958.
• Weber MA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211–20. Well designed clinical trial to evaluate BP lowering effects of an SGLT2 and try to estabish a mechanism in people with normal kidney function.
•• Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26(1):27–38. Excellent basic science review of metabolic pathways and how SGLT2 inhibitors may provide reduced CV risk.
Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Barsotti E, Clerico A, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40(6):771–6. https://doi.org/10.2337/dc16-2724.
Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(11):1087–95. https://doi.org/10.1111/dom.12322.
Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62. https://doi.org/10.1111/dom.12127.
•• Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508. https://doi.org/10.1172/JCI72227. A very important study that for the first time shows how lactate production may contribute to the benefit of heart failure outcomes with SGLT2 inhibition.
Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38(10):2265–76. https://doi.org/10.1016/j.clinthera.2016.09.001.
Kawasoe S, Maruguchi Y, Kajiya S, Uenomachi H, Miyata M, Kawasoe M, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017;18(1):23. https://doi.org/10.1186/s40360-017-0125-x.
•• Pfeifer M, et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29. Evaluation of biomarkers that help support benefit of SGLT2 inhibitors on improving vascular compliance.
Villafana S, Huang F, Hong E. Role of the sympathetic and renin angiotensin systems in the glucose-induced increase of blood pressure in rats. Eur J Pharmacol. 2004;506(2):143–50. https://doi.org/10.1016/j.ejphar.2004.10.055.
Yoshikawa T, Kishi T, Shinohara K, Takesue K, Shibata R, Sonoda N, et al. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertens Res. 2017;40(7):646–51. https://doi.org/10.1038/hr.2017.14.
Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11(11):e0165703. https://doi.org/10.1371/journal.pone.0165703.
Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1–3):246–55. https://doi.org/10.1016/j.ejphar.2013.05.014.
Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet. Diabetologia. 2017;60(2):364–76. https://doi.org/10.1007/s00125-016-4158-2.
•• Matthews, V.B., et al., Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens, 2017. Important paper that provides some of the first good data to argue that SGLT2 inhibitors reduces sympathetic tone.
Evan AP, et al. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 2005;67(2):576–91. https://doi.org/10.1111/j.1523-1755.2005.67114.x.
Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31. https://doi.org/10.1210/jc.2011-2260.
Evan AP, Coe FL, Lingeman JE, Shao Y, Matlaga BR, Kim SC, et al. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int. 2006;69(12):2227–35. https://doi.org/10.1038/sj.ki.5000268.
Evan AP, Lingeman JE, Worcester EM, Sommer AJ, Phillips CL, Williams JC, et al. Contrasting histopathology and crystal deposits in kidneys of idiopathic stone formers who produce hydroxy apatite, brushite, or calcium oxalate stones. Anat Rec (Hoboken). 2014;297(4):731–48. https://doi.org/10.1002/ar.22881.
Worcester EM, Evan AP, Coe FL, Lingeman JE, Krambeck A, Sommers A, et al. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I. Am J Physiol Renal Physiol. 2013;305(11):F1574–84. https://doi.org/10.1152/ajprenal.00382.2013.
• Kosiborod M, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249–59. Very well done database analysis to evaluate CV outcomes with all SGLT2 inhibitors.
Stankus N, Hammes M, Gillen D, Worcester E. African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III. Urol Res. 2007;35(2):83–7. https://doi.org/10.1007/s00240-007-0079-3.
Yamout H, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40(1):64–74.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Alexandros Briasoulis and Omar Al Dhaybi declare that they have no conflict of interest.
George L. Bakris has been a consultant for AbbVie Janssen, Relypsa, and Bayer.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Hypertension
Rights and permissions
About this article
Cite this article
Briasoulis, A., Al Dhaybi, O. & Bakris, G.L. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep 20, 1 (2018). https://doi.org/10.1007/s11886-018-0943-5
Published:
DOI: https://doi.org/10.1007/s11886-018-0943-5